Allogene Therapeutics ALLO Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Allogene Therapeutics (ALLO) reported proceeds from exercises of stock options and other stock issuances of $4K in Q1 2026.
- What is the long-term trend for Allogene Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2021 to 2025), Allogene Therapeutics's proceeds from exercises of stock options and other stock issuances has grown at a -100.0% compound annual growth rate (CAGR), from $8.35M to $0.